Among these five targets, FGFR3 was a particularly attractive target as it was highly expressed in four of eight PDX models (57.4–158.2 FPKM) (Fig 5B), and approximately 50% of primary bladder cancers [29]. The gene discussed is FGFR3; the disease is urinary bladder carcinoma.